Gilead, Galapagos to Present Latest Data on Filgotinib at Euro Rheumatology Meet

— Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions —

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.

“These data reinforce our belief that filgotinib has the potential to make a meaningful difference for patients with rheumatoid arthritis, both early and also late in the course of treatment when other treatments have failed,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “The FINCH results reflect the growing strength and breadth of Gilead’s inflammation pipeline and our commitment to improving the outlook for patients living with inflammatory diseases – both with filgotinib and our other investigational compounds.”

https://www.marketscreener.com/GALAPAGOS-6464/news/Galapagos-Gilead-and-Galapagos-to-Present-Latest-Data-on-Filgotinib-at-the-Annual-European-Congres-28675990/